stocks logo

CPRX

Catalyst Pharmaceuticals Inc
$
20.970
-0.05(-0.238%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
21.135
Open
21.100
VWAP
20.90
Vol
908.60K
Mkt Cap
2.56B
Low
20.720
Amount
18.99M
EV/EBITDA(TTM)
7.62
Total Shares
118.12M
EV
2.05B
EV/OCF(TTM)
7.65
P/S(TTM)
5.08
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
139.90M
-1.35%
--
--
138.93M
+7.96%
--
--
140.44M
+14.45%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Catalyst Pharmaceuticals, Inc. (CPRX) for FY2025, with the revenue forecasts being adjusted by 0.66% over the past three months. During the same period, the stock price has changed by -10.58%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.66%
In Past 3 Month
Stock Price
Go Down
down Image
-10.58%
In Past 3 Month
4 Analyst Rating
up Image
58.94% Upside
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 33.33 USD with a low forecast of 31.00 USD and a high forecast of 35.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
up Image
58.94% Upside
Current: 20.970
sliders
Low
31.00
Averages
33.33
High
35.00
Baird
Joel Beatty
Buy
Maintains
$28 → $32
2025-03-03
Reason
Baird raised the firm's price target on Catalyst Pharmaceuticals to $32 from $28 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 report as its Firdapse and Agamree are poised for a strong 2025.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$35
2025-02-28
Reason
Stephens & Co.
Sudan Loganathan
Buy
Reiterates
$33
2025-02-27
Reason
Baird
Joel Beatty
Buy
Initiates
$28
2025-02-04
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$30 → $35
2025-01-10
Reason
B of A Securities
Jason Gerberry
Strong Buy
Reiterates
$30
2025-01-09
Reason

Valuation Metrics

The current forward P/E ratio for Catalyst Pharmaceuticals Inc (CPRX.O) is 15.12, compared to its 5-year average forward P/E of 13.71. For a more detailed relative valuation and DCF analysis to assess Catalyst Pharmaceuticals Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
13.71
Current PE
15.12
Overvalued PE
18.17
Undervalued PE
9.25

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
2.83
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.17
Undervalued EV/EBITDA
-1.51

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.96
Current PS
0.00
Overvalued PS
4.85
Undervalued PS
3.08

Financials

Annual
Quarterly
FY2025Q1
YoY :
+43.56%
141.42M
Total Revenue
FY2025Q1
YoY :
+133.60%
63.37M
Operating Profit
FY2025Q1
YoY :
+143.77%
56.74M
Net Income after Tax
FY2025Q1
YoY :
+136.84%
0.45
EPS - Diluted
FY2025Q1
YoY :
+89.25%
60.04M
Free Cash Flow
FY2025Q1
YoY :
+3.75%
80.73
Gross Profit Margin - %
FY2025Q1
YoY :
+26.23%
50.05
FCF Margin - %
FY2025Q1
YoY :
+69.78%
40.12
Net Margin - %
FY2025Q1
YoY :
+100.07%
29.11
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
11.1M
USD
6
3-6
Months
7.0M
USD
4
6-9
Months
21.1M
USD
11
0-12
Months
5.8M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
3.2M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
2.1M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CPRX News & Events

Events Timeline

2025-06-02 (ET)
2025-06-02
08:31:39
Catalyst Pharmaceuticals appoints William Andrews as CMO
select
2025-05-07 (ET)
2025-05-07
17:15:21
Catalyst Pharmaceuticals backs FY25 revenue view $545M-$565M, consensus $557.23M
select
2025-05-07
17:13:48
Catalyst Pharmaceuticals reports Q1 EPS 68c, consensus 53c
select
Sign Up For More Events

News

6.5
07-24NASDAQ.COM
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group
4.0
07-02NASDAQ.COM
Validea Joel Greenblatt Strategy Daily Upgrade Report - 7/2/2025
2.0
07-01NASDAQ.COM
Catalyst Pharmaceuticals is Now Oversold (CPRX)
Sign Up For More News

FAQ

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX) stock price today?

The current price of CPRX is 20.97 USD — it has decreased -0.24 % in the last trading day.

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX)'s business?

arrow icon

What is the price predicton of CPRX Stock?

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX)'s revenue for the last quarter?

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Catalyst Pharmaceuticals Inc (CPRX)'s fundamentals?

arrow icon

How many employees does Catalyst Pharmaceuticals Inc (CPRX). have?

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX) market cap?